Answers are grounded in this paper and cite their sources.
This review explores antibody-drug conjugates and immune checkpoint inhibitors in metastatic urothelial carcinoma, highlighting their potential for personalized treatment.
Metastatic urothelial carcinoma (mUC) is a challenging malignancy with historically limited treatment options. Advances in understanding its biology have enabled the development of innovative therapies, including immune checkpoint inhibitors and antibody-drug conjugates (ADCs). ADCs, such as enfortumab vedotin, sacituzumab govitecan, and trastuzumab deruxtecan, represent transformative advancements, offering targeted delivery of cytotoxic agents. This review highlights the evolving role of ADCs in mUC, examining their mechanisms, clinical efficacy, patient selection criteria, genetic insights, and future directions in personalized treatment strategies.
No takes yet. Share an insight, caveat, or question.
D’Angelo et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: